

[OVERVIEW](#)

[PRESS RELEASES](#)

[EVENTS & PRESENTATIONS](#)

[CORPORATE GOVERNANCE](#)

[MANAGEMENT](#)

[BOARD OF DIRECTORS](#)

[COMMITTEE COMPOSITION](#)

[CONTACT THE BOARD](#)

[FINANCIAL INFORMATION](#)

[SEC FILINGS](#)

[ANNUAL REPORTS](#)

[QUARTERLY RESULTS](#)

[STOCK INFORMATION](#)

[HISTORIC STOCK LOOKUP](#)

[INVESTMENT CALCULATOR](#)

[ANALYST COVERAGE](#)

[INVESTOR FAQs](#)

[CONTACT US](#)

**CONTAGIOUS** *ideas*  
To Drive Therapy Compliance

## INVESTOR RELATIONS

### Investor Relations

Melinta Therapeutics, Inc. is dedicated to saving lives threatened by the global public health crisis of bacterial infections, through the development and commercialization of novel antibiotics that provide new and better therapeutic solutions. Melinta's lead product is Baxdela, an antibiotic approved by the US FDA for use in the treatment of acute bacterial skin and skin structure

infections (ABSSSI). Melinta also has an extensive pipeline of preclinical and clinical stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Together, this pipeline provides Melinta with the unique ability to provide doctors and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections.

## STOCK QUOTE


Price Change High

Nov 17, 2017 10:59 PM EST

[VIEW DETAILS](#)

Copyright Nasdaq. Minimum 15 minutes delayed.

## STOCK CHART



## PRESS RELEASES

November 13, 2017 [Melinta Therapeutics Reports First Patient Treated in Phase 2 Study of Topical Radezolid for Treatment of Acne](#)

November 06, 2017 [Melinta Therapeutics Announces Successful Completion of Merger](#)

November 03, 2017 [Cempra Announces Preliminary Results of 2017 Stockholder Vote](#)

## EVENTS & PRESENTATIONS

[FILTER](#)

[RESET](#)

There are currently no events to display.



梵

倭

宍

